Genomic stability in Mesenchymal Stromal Cells (MSCs) can be altered during their time in culture, raising issues. It can significantly reduce the cells’ differentiation potential, or have a detrimental impact on their therapeutic properties. It can also potentially impact patient safety in the long term (Neri, 2019).
G-Banding karyotyping is the gold standard for detecting abnormalities in mesenchymal stromal cells and provides a comprehensive assessment (balanced and unbalanced translocations, deletions, insertions and inversions).
However, if you need a faster solution at a lower cost, digital PCR can be an interesting alternative.
Detect over 80% of recurrent abnormalities in hMSCs in record-breaking time !
Ensure consistent cell line identity throughout your culture
Look deeper into any human cell type and detect targeted SNVs and Indels
Confidently detect mycoplasma in any human cell culture
According to Torre M L et al., the quality control process should be planned during the validation phase, during production and at batch release (Torre ML et al. 2017). This will ensure optimized MSC in-vitro culture conditions.
Mesenchymal Stromal Cells (MSCs) are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT).
They are also known as stromal/stem cells, medicinal signalling cells or in relation with their source, for instance “adipose-derived regenerative cells”.
In the 1960s, Friedenstein et al. identified a population of fibroblast-like cells that formed clonal colonies in vitro (CFU-F, Colony Forming Unit-Fibroblast) Friedenstein’s observations allowed for the discovery of a specific type of cell, currently referred to as mesenchymal stem cells (MSCs). MSCs are primary, non-specialized, non-hematopoietic, plastic-adherent cells with great proliferation potential and the capacity for self-renewal and differentiation. Source: Musiał-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019 Jul.
Stem Genomics recognizes the variety of needs coming from MSC laboratories. We have therefore designed an offer that not only meets your genomic detection needs, but also takes into account varying budget, performance and timescales expectations.
iCS-digital™ MSC range: Available in 24 probes, this unique test enables up to 80% detection of the most frequent genomic abnormalities in human mesenchymal stromal cells (hMSCs) in 3 days’ turnaround time. Available as a service only. More on iCS-digital™ MSC.
Join us LIVE for our webinar “Genomic stability made easy” to discover how Stem Genomics has turned cutting-edge technologies into easy testing solutions accessible to most labs.
Get expert opinions and user perspectives on our genomic stability assays in the context of iPSC research.
Happening on Tuesday, November 14, 6 pm CET
Please enter your e-mail address.